Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-21T13:25:38.105Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment Models and Patient Preferences

Published online by Cambridge University Press:  07 November 2014

Peter J. Weiden
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Clinical Information Monograph
Information
CNS Spectrums , Volume 10 , Issue 2 , February 2005 , pp. 10 - 16
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Harrison, G, Hopper, K, Craig, TJ. Recovery from psychotic illness: a 15 and 25 year international follow up study. Br J Psychiatry. 2001;178:506–518.CrossRefGoogle ScholarPubMed
2.Schooler, NR, Levine, J, Severe, JB, et al.Prevention of relapse in schizophrenia: An evaluation of fluphenazine decanoate. Arch Gen Psychiatry. 1980;37:16–24.CrossRefGoogle ScholarPubMed
3.Csernansky, JG, Schuchart, EK. Relapse and rehospitalization rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002;16(7):473–484.Google Scholar
4.Pigott, T, Carson, WH, Saha, AR, Torbeyns, A, Stock, E, Ingenito, GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048–1056.Google Scholar
5.Arato, M, O'Conner, R, Bradbury, J, Meltzer, H. Ziprasidone in the long-term treatment of of negative symptoms and prevention of exacerbation of schizophrenia. Eur Psychiatry. 1998;13(Suppl 4):303.CrossRefGoogle Scholar
6.McNeil, B, Pauker, SG, Sox, H, Tversky, A. On the elicitation of preferences for alternative therapies. N Eng J Med. 1982;306:1259–1262.Google Scholar
7.Fakhoury, WK, Wright, D, Wallace, M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom national mental health helpline. Int Clin Psychopharmacol. 2001;16(3):153–162.CrossRefGoogle ScholarPubMed
8.Weiden, P, Scheifler, P, Diamond, R, Ross, R. Breakthroughs in Antipsychotic Medications: A Guide for Consumers, Families, and Clinicians. New York, NY: Norton; 1999.Google Scholar
9.Kane, JM, Leucht, S, Carpenter, D, Docherty, JP. The Expert Consensus Guideline Series: Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64(Suppl 12):1–100.Google Scholar
10.Casey, DE, Carson, WH, Saha, AR, et al.Switching patients to aripiprazole from other antipsychotic agents. Psychopharmacology. 2003;166:391–399.CrossRefGoogle ScholarPubMed
11.Weiden, PJ, Daniel, DG, Simpson, G, Romano, S. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;32(6):1–6.Google Scholar
12.Weiden, PJ, Loebel, A, Yang, R, Lebovitz, H. Course of weight and metabolic benefits one-year after switching to ziprasidone. Paper presented at: 157th Annual Meeting of the American Psychiatric Association; May 4, 2004; New York, NY.Google Scholar